Fusion Antibodies
plc
("Fusion"
or the "Company")
Result of General
Meeting
and
Total Voting
Rights
Fusion Antibodies plc (AIM: FAB),
specialists in pre-clinical antibody discovery, engineering and
supply for both therapeutic drug and diagnostic applications,
announces that at the general meeting of the Company, held
earlier today, all resolutions were duly passed.
Following the passing of the
resolutions, the Company has raised a total of £1,375,000 pursuant
to the Placing, details of which were announced by the Company on
14 February 2024.
Application has been made for
admission of the 34,375,000 Placing Shares to trading on AIM
("Admission"). It is
currently anticipated that Admission will become effective and that
dealings in the Placing Shares will commence on AIM at 8.00 a.m. on
7 March 2024.
Total voting rights
Following Admission, the number of
ordinary shares of 4p each in the capital of the Company (the
"Ordinary Shares") in issue
and number of voting rights will be 95,365,564. The
above figure may be used by shareholders as the denominator for the
calculations by which they will determine whether they are required
to notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure Guidance
and Transparency Rules.
Terms used but not defined in this announcement have the same
meaning as set out in the Company's announcement released at 07:00
on 14 February 2024.
Enquiries:
|
Fusion
Antibodies plc
|
www.fusionantibodies.com
|
|
Adrian Kinkaid, Chief Executive
Officer
Stephen Smyth, Chief Financial
Officer
|
Via Walbrook PR
|
|
|
|
|
Allenby
Capital Limited
|
Tel: +44 (0)20 3328 5656
|
|
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke/Joscelin Pinnington (Sales and
Corporate Broking)
|
|
|
|
|
|
|
|
|
Shard Capital
Partners LLP
|
|
|
Damon Heath (Joint Broker)
|
Tel: +44 (0)207 186 9952
|
|
|
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933 8780
or fusion@walbrookpr.com
|
|
Anna Dunphy
|
Mob: +44 (0)7876 741 001
|
|
|
|
About Fusion
Antibodies plc
Fusion is a Belfast based contract research
organisation ("CRO") providing a range of antibody engineering
services for the development of antibodies for both therapeutic
drug and diagnostic applications.
The Company's ordinary shares were admitted to
trading on AIM on 18 December 2017. Fusion provides a broad range
of services in antibody generation, development, production,
characterisation and optimisation. These services include antigen
expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary
CDRx TM platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin
out from Queen's University Belfast. The Company's mission is to
enable pharmaceutical and diagnostic companies to develop
innovative products in a timely and cost-effective manner for the
benefit of the global healthcare industry. Fusion Antibodies
provides a broad range of services in antibody generation,
development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on
combining the latest technological advances with cutting edge
science to deliver new platforms that will enable Pharma and
Biotech companies get to the clinic faster, with the optimal drug
candidate and ultimately speed up the drug development
process.